Seed · Biotech · Munich, Germany · Founded 2022 · 6–10 employees
Invitris is a Munich-based biotech company that has developed a universal technology platform called Phactory to synthesize proteins in vitro without living cells, making protein-based drug development over 10,000x more efficient at 100x lower material costs. The company focuses on creating synthetic bacteriophages and antimicrobial proteins to combat antibiotic-resistant infections, addressing a major global health threat. Founded by Patrick Grossmann and Kilian Vogele as a spin-out from TUM, the company was accepted into Y Combinator and has raised funding from multiple sources including €250,000 from the INCATE consortium and investments from Mergus Ventures.